SCHEMBL6754583

SCHEMBL6754583

CCCOC(Cc1ccc(CCN2c3sccc3CCc3ccsc32)cc1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PPARG P37231 17/20 0.48
PPARA Q07869 14/20 0.41
PTPRF P10586 1/20 0.39
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
PPARD Q03181 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6754560 0.92 PPARG (0.54) PPARGPPARAPPARD
SCHEMBL6752623 0.89 PPARG (0.62) PPARGPPARAPPARD
SCHEMBL6753186 0.88 PPARG (0.46) PPARGPPARAPTPRFPTPN2PTPN1
SCHEMBL7516718 0.87 PPARG (0.41) PPARGPPARAPTPRFPTPN2PTPN1
SCHEMBL6748838 0.85 PPARG (0.46) PPARGPPARAPPARD
SCHEMBL6753211 0.85 PPARG (0.56) PPARGPPARAPPARD
SCHEMBL6748811 0.83 PPARG (0.57) PPARGPPARAPPARD
SCHEMBL6753209 0.82 PPARG (0.58) PPARGPPARAPPARD
SCHEMBL6752637 0.82 PPARG (0.72) PPARGPPARAPPARD
SCHEMBL6752433 0.81 PPARG (0.44) PPARGPPARAPTPRFPTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020065268-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-05-30 US claimed
US-20020065267-A1 Compounds, their preparation and use JEPPESEN LONE (DK) 2002-05-30 US claimed
US-20020061880-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-05-23 US claimed
US-20020061876-A1 Compounds, their preparation and use JEPPESEN LONE (DK) 2002-05-23 US claimed
US-20020055502-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-05-09 US claimed
US-6703401-B2 USEFUL IN THE TREATMENT AND/OR PREVENTION OF CONDITIONS MEDIATED BY CLEAR RECEPTORS, IN PARTICULAR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR). NOVO NORDISK A/S (DK) 2004-03-09 US disclosed
US-20020065268-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-05-30 US disclosed
US-20020065267-A1 Compounds, their preparation and use JEPPESEN LONE (DK) 2002-05-30 US disclosed
US-20020061880-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-05-23 US disclosed
US-20020061876-A1 Compounds, their preparation and use JEPPESEN LONE (DK) 2002-05-23 US disclosed
US-20020055502-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-05-09 US disclosed
US-6365586-B1 REDUCE BLOOD GLUCOSE AND TRIGLYCERIDE LEVELS AND ARE USEFUL FOR THERAPY OF AILMENTS AND DISORDERS SUCH AS DIABETES AND OBESITY NOVO NORDISK A/S (DK) 2002-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061880-A1 New compounds, their preparation and use PPARG, PPARD, PPARA PPARG 1/4885PPARA 3/4885PTPRF 2787/4885
US-20020065267-A1 Compounds, their preparation and use PPARG, PPARA, PPARD PPARG 1/4885PPARA 2/4885PTPRF 2681/4885
US-20020061876-A1 Compounds, their preparation and use PPARG, PPARA, PPARD PPARG 1/4885PPARA 2/4885PTPRF 2681/4885
US-20020055502-A1 New compounds, their preparation and use PPARG, PPARD, PPARA PPARG 1/4885PPARA 3/4885PTPRF 2776/4885
US-20020065268-A1 New compounds, their preparation and use PPARG, PPARD, PPARA PPARG 1/4885PPARA 3/4885PTPRF 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.